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Brief Communication
Clinical Relevancy Statement
Malnutrition is common in maintenance hemodialysis (MHD) 
patients and adversely affects their prognosis. Most patients on 
dialysis have a lower than normal dietary energy and protein 
intake. Renal-specific oral nutrition supplements (RS-ONS) 
are required to achieve intake recommendations. The present 
study clearly indicates that long-term RS-ONS improves the 
nutrition status of MHD patients with malnutrition.
Introduction
Malnutrition is common in patients with chronic kidney dis-
ease (CKD) and adversely affects their prognosis.1-3
Some patients on dialysis have a lower than normal dietary 
energy intake (DEI) and dietary protein intake (DPI), and oral 
nutrition supplements (ONS) are required to achieve intake rec-
ommendations.4 Clinical guidelines and literature reviews sup-
port enteral nutrition (EN) in patients with renal failure who 
were diagnosed with malnutrition,5 but there is no consensus on 
the type, time of initiation, or duration of use. In addition, the 
benefit of renal-specific ONS (RS-ONS) support in patients 
without clinical evidence of malnutrition is still unclear.
There are limited ONS clinical trials for dialysis patients.6-14 
In most of these studies, enteral therapy was associated with 
improved nutrition status. The aim of this study was to evalu-
ate the nutrition effects of RS-ONS on various outcomes in 
maintenance hemodialysis (MHD) patients. Based on the 
hypothesis that daily RS-ONS would prevent or reduce further 
deterioration of nutrition status of these patients, the present 
study was designed to compare the effects of RS-ONS and a 
standard recommended nutrition regime on biochemical and 
nutrition markers in malnourished patients with CKD on 
MHD.
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Abstract
Background: There is no consensus on the type, time of initiation, or duration of use of enteral nutrition in patients with chronic 
kidney disease (CKD). This study aimed to compare the effects of a renal-specific oral nutrition supplement (RS-ONS) and a standard 
recommended nutrition regime on biochemical and nutrition markers in malnourished patients with CKD on hemodialysis. Methods: 
Sixty-two malnourished patients with CKD, divided into experimental (RS-ONS; n = 32; mean [SD] age, 62.0 [11.3] years; 55.2% female) 
and control (CON; n = 30; mean [SD] age, 57.2 [12.3] years; 31% female) groups, were evaluated for anthropometric, biochemical, and 
inflammatory parameters. Results: Mean (SD) serum albumin levels were significantly increased in the RS-ONS group from 3.5 (0.3) g/
dL at baseline to 3.7 (0.2) g/dL at 6 months (P = .028). Significantly fewer patients had serum albumin levels of <3.5 g/dL after month 6. 
Dry weight of patients significantly increased in the RS-ONS but decreased in the CON groups (P < .001 for each). Percent change from 
baseline revealed negative results for bioelectrical impedance analysis (P < .001) in the CON group. Malnutrition inflammation score at 
6 months (P = .006) and erythropoietin (EPO) dose requirements were higher in the CON group (P = .012). Conclusions: Our findings 
indicate that consuming RS-ONS improves serum albumin and anthropometric measures, as well as reduces EPO dose, in patients with 
CKD. (JPEN J Parenter Enteral Nutr. 2014;38:960-965)
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Materials and Methods
Study Population
Among 286 MHD patients, 62 who were diagnosed as mal-
nourished (serum albumin concentration <4 g/dL and/or a loss 
of ≥5% dry weight [DW] over the past 3 months) were fol-
lowed up for 6 months between January and July 2011. 
Exclusion criteria were as follows: acute infection; chronic 
inflammatory disease of unknown origin; recent surgery within 
3 months or during follow-up; hospitalization, major cardio-
vascular event, or death during follow-up; nephrotic syndrome; 
malignancy history; and chronic liver disease.
All inpatients were recommended to use ONS. Nutrition data 
of patients who agreed to use ONS (n = 32; RS-ONS study 
group) and those who chose to increase their dietary intake 
instead (n = 30; control [CON] group) were analyzed (Figure 1). 
Twenty-nine patients in each group completed the study. 
Demographic data were obtained from patient files.
Each serving (200 mL) of RS-ONS preparation (Nutrena; 
Abbott Nutrition, Zwolle, Holland) contained 400 kcal, 14 g 
protein, 41.3 g carbohydrate, and 19.2 g fat and had lower con-
centrations of sodium, potassium, and phosphorus than standard 
ONS. In the RS-ONS group, 24 patients took 2 daily servings of 
RS-ONS, whereas 5 patients took 3 daily servings for 6 months. 
At each dialysis session, RS-ONS consumption and compliance 
were recorded. A snack providing approximately 300 kcal, 14 g 
protein, 55 g carbohydrate, and 10 g fat was served to patients 
during the sessions. Each patient consulted monthly with a dieti-
tian to achieve the target calorie intake of 35 kcal/kg/d.
Written informed consent was obtained from each subject 
following a detailed explanation of the protocol of the study 
conducted in accordance with the ethical principles stated in 
the Declaration of Helsinki and approved by Baskent University 
Institutional Review Board (project no. KA11/253).
Anthropometric Measurements
DW and intradialytic weight gain (IDWG) were measured at 
every MHD session, and monthly average for each patient was 
recorded. Body mass index (BMI) was calculated at the begin-
ning and end of follow-up period. Triceps skinfold thickness 
(TSFT)15 was measured from the arm without an arteriovenous 
fistula and at half-distance between the acromion and the olec-
ranon with a Harpenden caliper (Holtain, Chymycin, UK). 
Anthropometric and bioelectrical impedance analysis (BIA)16 
measurements were performed within 30 minutes after dialy-
sis. Body composition (fat mass [FM], fat-free mass [FFM], 
muscle mass [MM], and bone mass [BM]) was measured using 
the Tanita BC-420MA Body Composition Analyzer (Tanita, 
Tokyo, Japan). For the BIA measurements, the subject stood 
upright with bare feet on the analyzer footpads. The impedance 
between the feet was measured while an alternating current (50 
kHz and ~200 µA) passed through the lower body. FM, FFM, 
MM, and BM were computed with this impedance value.
Clinical and Biochemical Measurements
Predialysis serum concentrations of hemoglobin; creatinine; 
intact parathyroid hormone; total, low-density lipoprotein 
(LDL), and high-density lipoprotein (HDL) cholesterol; tri-
glyceride; serum albumin; C reactive protein (CRP); and trans-
ferrin saturation levels were assessed and mean erythropoietin 
dose received was recorded monthly. Each patient’s malnutri-
tion and inflammation score17 (MIS), which was created using 
the 7 components of the conventional Subjective Global 
Assessment (SGA) and combined with 3 new elements—body 
mass index (BMI), serum albumin, and total iron-binding 
capacity (TIBC) and normalized protein catabolic rate18 
(nPCR)—were calculated at baseline and at the end of the 
follow-up.
Statistical Analysis
Statistical Package for Social Sciences (version 14.0; SPSS, 
Inc, an IBM Company, Chicago, IL) was used. The sample size 
of the study was based on the MHD patients (n = 286) in our 
center. Data were submitted to a frequency distribution analy-
sis by the Kolmogorov-Smirnov test. Values displaying normal 
distribution were expressed as mean (standard deviation [SD]), 
and values with skewed distribution were expressed as median 
(interquartile range [IQR]). No method was defined for miss-
ing data. Normally distributed numeric variables were ana-
lyzed by independent samples t or 1-way analysis of variance 
Figure 1. Study flowchart. RS-ONS, renal-specific oral nutrition 
supplement.
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(ANOVA) (post hoc Tukey) tests according to distribution nor-
mality. Skew distributed numeric variables were compared 
using Mann-Whitney U and Kruskal-Wallis tests according to 
distribution normality. Related data were compared with paired 
samples t or Wilcoxon tests. Categorical data were compared 
by χ2 test, and P < .05 was considered statistically significant.
Results
Baseline Characteristics
Mean (SD) age in the RS-ONS group was 62.0 (11.3) years 
(55.2% female) in the RS-ONS group and 57.2 (12.3) years 
(31% female) in the CON group. No significant differences 
were found in age, sex, duration of MHD, basal urea reduction 
ratio (URR), MIS, and BMI (Table 1).
Biochemical Findings
Mean (SD) levels of serum albumin were significantly 
increased in the RS-ONS group from 3.5 (0.3) g/dL at baseline 
to 3.7 (0.2) g/dL at 6 months (P = .028) but not changed in the 
CON group. Serum albumin levels at 6 months were signifi-
cantly higher in the RS-ONS group compared with the CON 
group (3.7 [0.2] vs 3.5 [0.3] g/dL; P = .012) (Table 2).
Following RS-ONS initiation, there was a significant increase 
in serum albumin from months 1–6 (P = .012) (Figure 2). 
Although RS-ONS and CON groups were similar in terms of 
the percentage of patients with serum albumin levels <3.5 g/dL 
at baseline (48.3% vs 58.6%, respectively; P = .430), the 
RS-ONS group had significantly fewer such patients at month 
6 compared with the CON group (17.2% vs 48.3%; P = .012) 
(Figure 3).
Considering lipid only, mean (SD) serum LDL-cholesterol 
levels were higher in the RS-ONS group (93.4 [30.1] mg/dL) 
at the end of the study (P = .028) but still within normal limits 
(<160.0 mg/dL). The CON group had a significant accretion in 
mean (SD) transferrin saturation ratios from 36.8% (26.7%) at 
baseline to 55.6% (48.1%) at month 6 (P = .049). Dialysis 
adequacy did not differ between groups at any time (P = .968 
and P = .567, respectively) (Table 2).
Anthropometrical Measurements
At baseline, DW in the RS-ONS group was significantly lower 
than that in the CON group (P = .034), but at 6 months, a sig-
nificant increase in the RS-ONS but a decrease in the CON 
group was observed (P < .001 for each) (Table 2).
BMI of the 2 groups was similar at baseline (P = .355); the 
CON group exhibited a significant decrease from baseline to 
month 6 (P < .001), while BMI remained stable in the RS-ONS 
group. The RS-ONS group’s TSFT significantly increased at 
the end of the study, but the CON group had a significant 
decline from 12.6 (5.4) to 11.3 (5.5) cm (P < .001 for both). At 
baseline, the CON group had significantly higher levels of 
FFM, MM, and BM. During the 6 months of the study, FFM, 
MM, and BM remained stable in the RS-ONS group while the 
CON group experienced significant declines in all (P < .001 
for each) (Table 2).
Percent changes from baseline values in DW, BMI, and BIA 
measurements, including FFM, MM, and BM, were negative 
in the CON group (P < .001 for each) (Figure 4).
Malnutrition and inflammation scores were similar in both 
groups at baseline (P = .682) but increased significantly in the 
CON group at month 6 (P = .006) while remaining stable in the 
RS-ONS group. nPCR was similar between the 2 groups at 
baseline (P = .487). Although there were numerical decreases 
in the nPCR level during the study period in the CON group, 
the change did not reach statistical significance (P = .097). 
Although hemoglobin levels of both groups did not show sta-
tistically significant changes during the study, the CON group 
required significantly higher erythropoietin doses compared 
with the RS-ONS group (P = .012) to maintain steady hemo-
globin levels (Table 2).
Adverse Events
The most frequent adverse events in the RS-ONS group were 
digestive symptoms, mainly diarrhea, nausea, and abdominal 
distention, as observed in 5 patients. They were recommended 
to decrease the dose of RS-ONS to 1 can/d, and in 3 cases, 
RS-ONS was discontinued. In addition, 1 patient in the CON 
group died of an acute cerebrovascular event.
Table 1. Demographical and Clinical Characteristics of All 
Subjects at Baseline.
Characteristic
RS-ONS 
Group (n = 29)
CON Group 
(n = 29)
P 
Value
Age, mean (SD), y 62.0 (11.3) 57.2 (12.3) .130
Male sex, No. (%) 13 (44.8) 20 (69) .063
Duration of HD, mean (SD), y 6.5 (4.9) 9.4 (8.7) .127
Etiology of CKD, No. (%) .986
 Diabetes mellitus 5 (17.2) 4 (13.8)  
 Hypertension 9 (31.0) 8 (27.5)
 Glomerulonephropathy 4 (13.8) 6 (20.6)
 Unknown reason 2 (6.9) 1 (3.4)
 Other reasonsa 9 (31.0) 10 (34.4)
URR, mean (SD) 68.3 (6.7) 68.2 (6.4) .968
MIS, mean (SD), points 8.3 (2.8) 7.3 (2.7) .169
BMI, mean (SD), kg/m2 22.7 (4.0) 23.8 (4.7) .355
BMI, body mass index; CKD, chronic kidney disease; CON, control; HD, 
hemodialysis; MIS, malnutrition and inflammation score; RS-ONS, renal-
specific oral nutrition supplementation; SD, standard deviation; URR, 
urea reduction ratio.
aIncludes nephrolithiasis, polycystic kidney disease, renal artery stenosis, 
systemic lupus erythematosus, tubulointerstitial nephritis, vesicoureteral 
reflux, familial Mediterranean fever, and Fabry disease.
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Table 2. Laboratory Findings, Anthropometric Indicators, MIS, nPCR, and Erythropoietin Requirement in RS-ONS and CON Groups: 
Baseline and 6-Month Comparison Between and Within Groups.
RS-ONS Group CON Group  
Measurement Baseline 6 Months Baseline 6 Months P Value
Hemoglobin, g/dL 11.1 (1.2) 11.3 (1.2) 10.7 (1.7) 10.7 (1.5) —
Creatinine, mg/dL 7.5 (2.0) 7.5 (1.8) 8.8 (2.3) 8.4 (2.5) .031a
Intact PTH, pg/mL 652.1 (688.1) 546.0 (519.3) 770.6 (738.8) 694.3 (638.6) —
Total cholesterol, mg/dL 160.1 (34.9) 164.2 (39.0) 149.9 (41.9) 148.1 (34.2) —
LDL-cholesterol, mg/dL 89.3 (30.1) 93.4 (30.1) 76.9 (24.0) 76.1 (28.4) .028b
HDL-cholesterol, mg/dL 38.9 (15.4) 39.6 (9.5) 34.8 (10.1) 37.1 (10.6) —
Triglyceride, mg/dL 125.0 (64.0) 119.6 (59.7) 120.1 (72.9) 112.2 (50.6) —
Serum albumin, g/dL 3.5 (0.3) 3.7 (0.2) 3.4 (0.3) 3.5 (0.3) .012,b .028c
CRP, g/dL 6.0 (21.6) 7.4 (12.0) 6.1 (27.5) 11.0 (22.0) —
Lymphocyte, mm3 1410 (625) 1330 (755) 1500 (1000) 1670 (940) —
White blood cells, mm3 7219.7 (2253.2) 6724.8 (2427.6) 7014.5 (1809.1) 6568.6 (2082.0) —
Transferrin saturation, % 47.82 (65.1) 54.4 (34.4) 36.8 (26.7) 55.6 (48.1) .049d
URR 68.3 (6.7) 68.2 (6.4) 70.7 (6.6) 69.7 (5.6) —
Dry weight, kg 58.1 (10.3) 59.0 (10.4) 65.5 (15.2) 63.9 (15.0) .034,a <.001c,d
Intradialytic weight gain, kg 2.9 (0.6) 3.1 (0.6) 3.0 (0.9) 3.0 (0.8) —
BMI, kg/m² 22.7 (4.0) 22.9 (3.7) 23.8 (4.7) 23.0 (4.5) <.001d
Triceps skinfold thickness, cm 10.5 (5.0) 11.9 (5.0) 12.6 (5.4) 11.3 (5.5) <.001c,d
Fat mass, kg 14.8 (8.8) 15.0 (8.9) 14.7 (10.1) 14.6 (9.8) —
Fat-free mass, kg 43.5 (6.8) 44.3 (6.9) 51.0 (9.1) 49.0 (9.2) <.001,a,d .030b
Muscle mass, kg 41.3 (6.5) 42.0 (6.4) 48.4 (8.6) 46.5 (8.8) <.001,a,d .028b
Bone mass, kg 2.2 (0.3) 2.3 (0.3) 2.6 (0.4) 2.5 (0.4) <.001,a,d .037b
MIS, score 8.3 (2.8) 8.2 (3.0) 7.3 (2.7) 8.8 (3.4) <.006d
nPCR, g/kg/d 0.91 (0.17) 0.93 (0.17) 0.94 (0.18) 0.89 (0.17) —
rHuEPO dose change, % –14.77 (35) 1.38 (24.14) .012b
Values are expressed as mean (SD). CON, control; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTH, 
parathyroid hormone; URR, urea reduction ratio; BMI, body mass index; MIS, malnutrition and inflammation score; nPCR, normalized protein catabolic 
rate; rHuEPO, recombinant human erythropoietin; IQR, interquartile range; RS-ONS, renal-specific oral nutrition supplementation; —, p >.05.
aP values for baseline comparison between groups.
bP values for 6-month comparison between groups.
cP values for baseline vs 6-month comparison in the RS-ONS group.
dP values for baseline vs 6-month comparison in the CON group.
Figure 2. Mean serum albumin concentration (g/dL) in oral 
nutrition supplementation (ONS) and control groups during the 
study period.
Figure 3. Percentage of patients with serum albumin level of 
<3.5 g/dL in oral nutrition supplementation (ONS) and control 
groups at baseline and month 6 of the study.
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Discussion
Our findings revealed that RS-ONS significantly improved 
nutrition parameters in malnourished patients with CKD, simi-
lar to a previous prospective study.11 Notably, several clinically 
undiagnosed nutrition parameters deteriorated in patients who 
declined nutrition supplementation.
Hypoalbuminemia is most likely the strongest predictor of 
mortality among MHD patients.19 Seven randomized and non-
randomized trials with ONS reported significant improvements 
in serum albumin levels.6-10,12,14 In our study population, a sig-
nificant increase in serum albumin was observed only in the 
RS-ONS group and a significant reduction in the percentage of 
patients with serum albumin <3.5 g/dL at the end of the follow-
up period. Therefore, it seems reasonable to consider the sig-
nificant improvement in serum albumin as well as nutrition 
status in patients receiving RS-ONS to result in lower inflam-
matory status.
Considering the suggested relation of anthropometrics,19-21 
it is worth noting that a significant increase in DW, BMI, and 
TSFT was evident in the RS-ONS group, while the CON group 
showed a significant decline.
BIA is an easy-to-implement and a useful nutrition assess-
ment tool to monitor health status, determine long-term fol-
low-up, and detect early losses of lean body mass in MHD 
patients.6 In this study, both groups were similar in terms of 
demographic and clinical data, and baseline and 6-month BIA 
values were higher in the CON group. The possible explana-
tion of this result may be that patients in the CON group might 
have been feeling better at the initiation of the study, with bet-
ter appetite and nutrition intake. But at the end of the study, 
while BIA values of the CON group significantly decreased, an 
increase of 1%–2% was observed in the experimental group.
Exploring the relationship between measures of body com-
position and anemia, we observed a 14.8% decrease in EPO 
dose for patients receiving RS-ONS.
The present study clearly indicates that RS-ONS improves 
the nutrition status of patients in MHD patients with malnutri-
tion. Albeit no relationship was determined between body 
composition and markers of inflammation, improvement of 
MIS and EPO requirement in the RS-ONS group seems 
notable.
Previously, our clinical approach was to advise an increase 
in nutrition intake when minor signs of malnutrition were 
detected in our patients. However, the present findings suggest 
that earlier introduction of RS-ONS improves nutrition status.
One of the limitations of this study is the higher baseline 
and 6-month BIA values in the CON group. The total daily 
protein/calorie intake was not assessed, and we did not use a 
more sensitive reference method to estimate body composition 
(like dual-energy x-ray absorptiometry).
Conclusion
In conclusion, our findings indicate that consuming RS-ONS 
at home improves the nutrition and inflammatory status of 
patients with CKD, which suggests development of a rational 
approach to detect minor signs of malnutrition early as well as 
a reasonable treatment strategy.
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